University of Queensland, School of Clinical Medicine, Brisbane, Queensland, Australia.
Metro South Addiction and Mental Health Service, Brisbane, Queensland, Australia.
Psychooncology. 2023 May;32(5):651-662. doi: 10.1002/pon.6120. Epub 2023 Mar 14.
The incidence and mortality rates of breast cancer in individuals with pre-existing severe mental illness (SMI), such as schizophrenia, bipolar disorder, and major depression, are higher than in the general population. Reduced screening is one factor but there is less information on possible barriers to subsequent treatment following diagnosis.
We undertook a systematic review and meta-analysis on access to guideline-appropriate care following a diagnosis of breast cancer in people with SMI including the receipt of surgery, endocrine, chemo- or radiotherapy. We searched for full-text articles indexed by PubMed, EMBASE, PsycInfo and CINAHL that compared breast cancer treatment in those with and without pre-existing SMI. Study designs included population-based cohort or case-control studies.
There were 13 studies included in the review, of which 4 contributed adjusted outcomes to the meta-analyses. People with SMI had a reduced likelihood of guideline-appropriate care (RR = 0.83, 95% CI = 0.77-0.90). Meta-analyses were not possible for the other outcomes but in adjusted results from a single study, people with SMI had longer wait-times to receiving guideline-appropriate care. The results for specific outcomes such as surgery, hormone, radio- or chemotherapy were mixed, possibly because results were largely unadjusted for age, comorbidities, or cancer stage.
People with SMI receive less and/or delayed guideline-appropriate care for breast cancer than the general population. The reasons for this disparity warrant further investigation, as does the extent to which differences in treatment access or quality contribute to excess breast cancer mortality in people with SMI.
患有精神障碍(SMI)的个体,如精神分裂症、双相情感障碍和重度抑郁症,其乳腺癌的发病率和死亡率高于一般人群。筛查减少是一个因素,但对于诊断后后续治疗可能存在的障碍,信息较少。
我们对 SMI 患者(包括接受手术、内分泌、化疗或放疗的患者)确诊乳腺癌后接受指南推荐治疗的情况进行了系统回顾和荟萃分析。我们检索了 PubMed、EMBASE、PsycInfo 和 CINAHL 索引的全文文章,比较了有和无预先存在 SMI 的患者的乳腺癌治疗情况。研究设计包括基于人群的队列或病例对照研究。
综述共纳入 13 项研究,其中 4 项研究提供了调整后的结局数据进行荟萃分析。SMI 患者接受指南推荐治疗的可能性降低(RR=0.83,95%CI=0.77-0.90)。其他结局无法进行荟萃分析,但在一项研究的调整结果中,SMI 患者接受指南推荐治疗的等待时间更长。手术、激素、放疗或化疗等特定结局的结果参差不齐,这可能是因为结果主要未调整年龄、合并症或癌症分期。
与一般人群相比,患有 SMI 的人接受的乳腺癌指南推荐治疗较少和/或延迟。需要进一步调查这种差异的原因,以及治疗机会或质量的差异在多大程度上导致 SMI 患者的乳腺癌死亡率过高。